Samsung C&T invests up to $100M in Kairos Power's Hermes 2 nuclear reactor in Tennessee, the first project under Google's 500 ...

SoftBank has drawn more than $20 billion of preliminary demand for what’s shaping up to be one of the biggest junk bond deals ever, as investors rush to capture record yields likely to be offered to ...

Chasing data independence may cost Europe more than it saves, especially with systems that must interoperate with international partners.

Arm's CEO says the Arm chip supply constraint, not demand, is capping AI chip revenue growth after his CNBC comments moved ...

The founder of TalkTalk and the broadband group's biggest lender are exploring a move to take control of its consumer-facing ...

You govern in prose,” said former New York Governor Mario Cuomo 40 years ago. Canada’s Prime Minister Mark Carney is now in ...

Issued on behalf of Western Star Resources Inc.VANCOUVER, British Columbia, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Equity Insider News Commentary - ...

The Paramount Skydance plan to absorb Warner Bros Discovery has turned a legal saga into a live test of what a bigger studio ...

Oregen Energy Corp. (CSE: ORNG) (FSE: A1S0) (OTCQB: ORGEF) ("Oregen" or the "Company") is pleased to announce its intention to complete a non-brokered private placement of up to 25,000,000 units for ...

Janux Therapeutics surged on promising early data and M&A rumors in 2024, but recent clinical updates led to a sharp stock decline. Click for more on JANX.

Initiate Cue Biopharma (CUE) with a Buy rating on strong phase 2 CUE-221 CSU data vs Xolair, key 2026 catalysts, and risks—click to read now.

The study will compare two AC-101 dose groups with a placebo arm.